Publications by authors named "I Trevino-Frenk"
Introduction: The primary objective of the core data set is to reduce heterogeneity and promote harmonization among data sources in EM, thereby reducing the time needed to execute real life data collection efforts. Recently, a group led by the Multiple Sclerosis Data Alliance has developed a core data set for collecting real-world data on multiple sclerosis (MS) globally. Our objective was to adapt this global data set to the needs of Latin America, so that it can be implemented by the registries already developed and in the process of development in the region.
View Article and Find Full Text PDFArticle Synopsis
- This study examines the effectiveness of six different therapies for treating relapsing-remitting multiple sclerosis (RRMS) over 5 years, using a large dataset from 74 centers across 35 countries.
- Researchers found that natalizumab and fingolimod were more effective in reducing relapses and worsening disability compared to other therapies like dimethyl fumarate, teriflunomide, glatiramer acetate, and interferon beta.
- The findings highlight the potential of marginal structural models (MSMs) to simulate clinical trials and compare various treatment outcomes in real-world patient populations.
Background: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trials and guide clinical decisions. Observational studies are, however, susceptible to confounding and bias. Among the used techniques to reduce indication bias are propensity score matching and marginal structural models.
View Article and Find Full Text PDFBackground And Purpose: This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS).
Methods: We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow-up ≥ 1 year, and Expanded Disability Status Scale (EDSS) score ≥ 3, with ≥1 score recorded per year.
Practical issues concerning the use of Magnetic Resonance Imaging in Multiple Sclerosis in Latin America: Discussion from 16 centres on behalf of the Foro Latam EM Study Group.
Mult Scler Relat Disord
March 2022
Article Synopsis
- Recent MAGNIMS-CMSC-NAIMS recommendations on MRI use in multiple sclerosis (MS) have been crucial for enhancing patient treatment.
- Implementation of these guidelines is inconsistent across various countries, indicating the need to tackle local challenges.
- A group of 14 MS neurologists from 16 centers in Latin America convened to evaluate MRI access, standardization of protocols, and opportunities for collaborative research in MS.